title: Improving therapy for patients with aggressive lymphoma.
abstract: The outcome for patients with diffuse large B-cell lymphomas improved dramatically in the last decade, and the opportunity for improving therapy for patients with peripheral T-cell lymphoma exists as we begin to study specific subtypes of the disease. It is entirely possible that patients with different genetic subtypes of diffuse large B-cell lymphoma will eventually require different treatments, and the same will be true for patients with subtypes of peripheral T-cell lymphoma. These possibilities will be the focus of clinical investigation over the next decade.
authors.affiliation: University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, USA. joarmita@unmc.edu
authors.forename: James O
authors.initials: JO
authors.lastname: Armitage
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007391:International Cooperation; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D016411:Lymphoma, T-Cell, Peripheral / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone